| Price | Lot Size | Issue Date | Issue Size |
|---|---|---|---|
| ₹372 to ₹392 | 38 | 24th Mar, 2026 – 27th Mar, 2026 | ₹409 Cr |
Sai Parenterals Ltd
Sai Parenterals is a pharmaceutical company engaged in the manufacturing of branded generic formulations and the provision of CDMO services to global pharma players. The company has built a diversified portfolio across key therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, anti-infectives, gastroenterology, VMS, analgesics, and dermatology, supported by a wide range of dosage forms such as injectables, tablets, capsules, liquid orals, dry syrups, and ointments, with capabilities in complex injectables, including vials and pre-filled syringes. Its business is driven by two segments: branded generics, primarily catering to the domestic market through government tenders, hospitals, and distributors, contributing the majority of revenues, and a rapidly growing CDMO segment offering end-to-end services, including product development, regulatory approvals, and manufacturing. The company commenced exports in 2023 following the acquisition of internationally approved facilities and has since expanded its presence across regulated and semi-regulated markets, including Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Further strengthening its global footprint, the company acquired a 74.6% stake in Australia-based Noumed, adding a portfolio of OTC products, long-term contracts, and stable revenues from regulated markets. The company operates five manufacturing facilities in India, including four in Hyderabad, with an aggregate installed capacity of ~1,160 mn units per annum. The plants are compliant with GMP and WHO-GMP standards, and is supported by strong R&D and quality control capabilities, enabling it to cater to both high-volume and high-value product segments while enhancing its positioning across domestic and international markets.
Objective of Sai Parenterals Ltd
The net proceeds from the fresh issue will be used towards the following purposes:
- Capacity expansion and upgradation of manufacturing facilities;
- Establishment of a new R&D Centre;
- Repayment and / or pre-payment, in full or part, of certain borrowings availed by the company;
- Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and
- General corporate purposes.
Rationale To Sai Parenterals Ltd
Investment Rationale
Well-diversified formulations player with a proven execution track record
Sai Parenterals has evolved into a diversified player in the generic formulations segment, supported by a proven track record of scalable growth driven by strategic transformation and strong operational execution. Established in 2001 as a parenteral-focused manufacturer, the company has significantly expanded its capabilities, product portfolio, and market presence under the current management since 2016. The transformation is reflected in its revenue growth from a modest base to ~Rs. 1,631 million in FY25, underpinned by diversification across dosage forms (injectables, tablets, capsules, liquid orals, and ointments) and therapeutic segments, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, anti-infectives, gastroenterology, VMS, analgesics, and dermatology. Following the strengthening of its manufacturing and marketing capabilities in FY23, aided by the acquisition of two internationally accredited facilities (Unit III and Unit IV), the company has successfully forayed into exports of branded generics and CDMO services across regulated and semi-regulated markets. It has established partnerships with multinational pharmaceutical companies under CDMO arrangements, which typically offer better revenue visibility and long-term stability. Over the years, the company has also witnessed steady expansion of its customer base, supporting revenue growth and improved operating efficiency. This growth has been driven by its cost-efficient manufacturing capabilities, ongoing capacity expansion, and disciplined cost control measures.
Scaling CDMO operations to drive sustainable and high-margin growth
The company’s strong and increasing focus on the CDMO segment presents a key investment driver, supported by its transition from domestic engagements in FY22 to international CDMO operations in FY23, enabled by the acquisition of two internationally accredited manufacturing facilities (Unit III and IV). This expansion has facilitated entry into regulated and semi-regulated markets while also strengthening its capabilities through the establishment of a dedicated FR&D facility, allowing it to offer end-to-end development and technical services. The company has further augmented its CDMO platform through the acquisition of Noumed, enhancing its presence in the OTC segment and providing access to regulated market portfolios. As of December 31, 2025, the company maintains active CDMO engagements with both domestic and international pharmaceutical players, with several relationships backed by long-term supply contracts, ensuring revenue visibility and stability. The company has growing intellectual property base, comprising 55 in-house developed dossiers (including 45 approved across key markets) and additional dossiers acquired through technology transfer agreements, along with access to 451 dossiers via Noumed. These dossiers provide a strong pipeline for product commercialization, market expansion, and sustained customer retention, thereby reinforcing the scalability and long-term growth potential of its CDMO business.
Valuation of Sai Parenterals Ltd
Sai Parenterals is a pharmaceutical company with a structurally evolving business model, transitioning from a parenteral-focused manufacturer to a diversified formulations and CDMO-driven player. The company has evolved from a parenteral-focused manufacturer into a multi-dosage, multi-therapy player with presence across domestic and export markets. The increasing engagement with multinational clients through CDMO contracts provides better revenue visibility and stability due to long-term agreements. Its end-to-end capabilities spanning product development, regulatory filings, and manufacturing position it well to benefit from rising global outsourcing trends, particularly as it expands into regulated markets supported by upgraded facilities and strengthened R&D infrastructure. The company is also focused on capacity expansion, regulatory accreditations, and development of complex injectable capabilities, which are expected to improve product mix and margins by enabling entry into high-value segments. Additionally, its acquisition-led strategy, including the integration of Noumed, strengthens its global footprint, provides access to an expanded dossier base, and supports long-term growth in the CDMO segment. From an industry perspective, the global CDMO market is projected to witness robust growth, expanding from ~US$297 bn in 2025 to over ~US$609 bn by 2033 (CAGR ~9.4%), driven by increasing outsourcing by global pharmaceutical companies and a rising contribution from cost-competitive emerging markets such as India. Improving regulatory compliance and manufacturing capabilities in these regions further strengthen their positioning in the global supply chain. On the financial front, the company has delivered strong growth, reporting a CAGR of 29.8%/45.8%/81.6% in revenue/EBITDA/PAT over FY23-FY25 period, supported by customer additions, improved capacity utilization, and operating leverage. Going ahead, an increasing contribution from CDMO revenues and exports is expected to enhance the margin profile while reducing dependence on the domestic tender-driven business. Additionally, scale benefits and ongoing cost efficiencies are likely to support profitability over the medium term. Overall, Sai Parenterals appears well-positioned to deliver sustainable growth, driven by a rising CDMO mix, expansion into regulated markets, continued capacity and R&D investments, and acquisition-led global integration. On the upper price band, the issue is valued at a P/E of 72.2x based on FY25 earnings. We, thus, recommend a “SUBSCRIBE” rating for this issue.
What is the Sai Parenterals Ltd IPO?
The initial public offer (IPO) of Sai Parenterals Ltd offers an early investment opportunity in. A stock market investor can buy Sai Parenterals Ltd IPO shares by applying in IPO before All Sai Parenterals Ltd shares get listed at the stock exchanges. An investor could invest in Sai Parenterals Ltd for short term listing gain or a long term.
How to apply for the Sai Parenterals Ltd IPO through StoxBox?
To apply for the Sai Parenterals Ltd IPO through StoxBox one can apply from the website and also from the app. Click here
When will the Sai Parenterals Ltd IPO open?
Sai Parenterals Ltd IPO is opening on 24th Mar 2026. Apply Now
What is the lot size of the Sai Parenterals Ltd IPO?
The Lot Size of Sai Parenterals Ltd is 38 equity shares. Login to your account now.
When is the Sai Parenterals Ltd IPO allotment date?
The allotment Date for Sai Parenterals Ltd IPO is 30th Mar 2026. Login to your account now.
When is the Sai Parenterals Ltd IPO listing date?
The listing Date for Sai Parenterals Ltd is 2nd Apr 2026. Login to your account now
What is the minimum investment required for the Sai Parenterals Ltd IPO?
In the Retail segment the minimum investment required is Rs. 14,896. Login to your account now
What is the maximum investment allowed for Sai Parenterals Ltd IPO?
In the Retail segment the maximum investment requirement is Rs. 1,93,648. Login to your account now
What are the risks associated with investing in the Sai Parenterals Ltd IPO?
- The company manufacturing facilities are primarily concentrated in Hyderabad and Andhra Pradesh. Any adverse developments in these regions including economic slowdowns, regulatory changes, political instability, operational disruptions, or natural disasters could lead to production interruptions and supply chain challenges.
- The company’s manufacturing facilities are subject to periodic inspections and audits by regulatory authorities and customers. Any adverse observations, non-compliance, or failure to meet required standards may result in regulatory actions, including warnings, penalties, or operational restrictions.
- The company procures key raw materials, including APIs, excipients, and intermediates, from a diversified supplier base without entering into long-term contractual agreements. Any disruption, reduction, or discontinuation of supplies from key suppliers may lead to production challenges and could materially impact business operations.
When will the Sai Parenterals Ltd IPO shares be credited to my Demat account?
The Sai Parenterals Ltd will be credited to the account on allotment date which is 30th Mar 2026. Login to your account now
Where can I find the Sai Parenterals Ltd IPO prospectus?
The prospectus of Sai Parenterals Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE
